ReviewInternational journal of molecular sciences2022
Recent Advances in Light-Controlled Activation of Pt(IV) Prodrugs.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Comparative study of the direct and photocatalytic light activation of platinum(IV) prodrugs.Dalton transactions (Cambridge, England : 2003) · 2026Article
- Heavy-Atom-Free Dual-Action Dual PACT/PDT action Pt(IV) Prodrug With BODIPY Dimer in Axial Position.ChemMedChem · 2026Article
- Nanocarrier-based delivery of Pt(IV) compounds for chemoimmunotherapy and theranostics: Advances, challenges, and prospects.Acta pharmaceutica Sinica. B · 2026Review
- Asymmetrically Disubstituted Pyrenebutyrate Complexes of Pt(IV) as Cisplatin Prodrugs with Improved Anticancer Activity.Molecules (Basel, Switzerland) · 2026Article
- DFTB Parametrization at the Example of Platinum-Implementation, Validation and Practical Considerations.Journal of computational chemistry · 2026Article
- Novel Cytotoxic Pt(IV) Compounds with Improved Safety Profiles.International journal of molecular sciences · 2026Article
- Colorectal Cancer at the Crossroads: The Good, the Bad, and the Future of Platinum-Based Drugs.Chemical reviews · 2025Review
- Advancements in Biomaterials for Bioengineering and Biotechnology.International journal of molecular sciences · 2024Article
- Current Status of Novel Multifunctional Targeted Pt(IV) Compounds and Their Reductive Release Properties.Molecules (Basel, Switzerland) · 2024Review
- Oxidation of the Platinum(II) Anticancer Agent [Pt{(Molecules (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Pt(IV) prodrugs remain one of the most promising alternatives to conventional Pt(II) therapy due to their versatility in axial ligand choice and delayed mode of action. Selective activation from an external source is especially attractive due to the opportunity to control the activity of an antitumor drug in space and time and avoid damage to normal tissues. In this review, we discuss recent advances in photoabsorber-mediated photocontrollable activation of Pt(IV) prodrugs. Two main approaches developed are the focus of the review. The first one is the photocatalytic strategy based on the flavin derivatives that are not covalently bound to the Pt(IV) substrate. The second one is the conjugation of photoactive molecules with the Pt(II) drug via axial position, yielding dual-action Pt(IV) molecules capable of the controllable release of Pt(II) cytotoxic agents. Thus, Pt(IV) prodrugs with a light-controlled mode of activation are non-toxic in the absence of light, but show high antiproliferative activity when irradiated. The susceptibility of Pt(IV) prodrugs to photoreduction, photoactivation mechanisms, and biological activity is considered in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.